Supplemental Information from Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Thomas A. Werfel(University of Mississippi Medical Center), Craig L. Duvall(Vanderbilt University), Taylor E. Kavanaugh(Vanderbilt University), Linus H. Lee, Somtochukwu C. Dimobi(Vanderbilt University), Violeta Sánchez(Vanderbilt University), Donna J. Hicks(Vanderbilt University), Meghan M. Joly(UL Research Institutes), Samantha M. Sarett(Vanderbilt University), Rebecca S. Cook(Vanderbilt University), Meredith A. Jackson(Vanderbilt University), Dana M. Brantley‐Sieders(Susan G. Komen Breast Cancer Foundation), Shan Wang(Island Hospital), Kameron V. Kilchrist(Vanderbilt University)
Cited by 0
Related Papers
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling
|Journal of Clinical Investigation|2008|276
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
|Cancer Research|2021|256